51
|
Chen B, Pan P, Wang L, Chen M, Dong Y, Ge RS, Hu GX. Effects of Methoxychlor and 2,2-bis ( p-Hydroxyphenyl)-1,1,1-Trichloroethane on Cytochrome P450 Enzyme Activities in Human and Rat Livers. Pharmacology 2015; 95:145-53. [DOI: 10.1159/000380883] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 02/01/2015] [Indexed: 11/19/2022]
|
52
|
Bachmann A, Moll M, Gottwald E, Nies C, Zantl R, Wagner H, Burkhardt B, Sánchez JJM, Ladurner R, Thasler W, Damm G, Nussler AK. 3D Cultivation Techniques for Primary Human Hepatocytes. MICROARRAYS (BASEL, SWITZERLAND) 2015; 4:64-83. [PMID: 27600213 PMCID: PMC4996383 DOI: 10.3390/microarrays4010064] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Revised: 01/08/2015] [Accepted: 02/03/2015] [Indexed: 01/27/2023]
Abstract
One of the main challenges in drug development is the prediction of in vivo toxicity based on in vitro data. The standard cultivation system for primary human hepatocytes is based on monolayer cultures, even if it is known that these conditions result in a loss of hepatocyte morphology and of liver-specific functions, such as drug-metabolizing enzymes and transporters. As it has been demonstrated that hepatocytes embedded between two sheets of collagen maintain their function, various hydrogels and scaffolds for the 3D cultivation of hepatocytes have been developed. To further improve or maintain hepatic functions, 3D cultivation has been combined with perfusion. In this manuscript, we discuss the benefits and drawbacks of different 3D microfluidic devices. For most systems that are currently available, the main issues are the requirement of large cell numbers, the low throughput, and expensive equipment, which render these devices unattractive for research and the drug-developing industry. A higher acceptance of these devices could be achieved by their simplification and their compatibility with high-throughput, as both aspects are of major importance for a user-friendly device.
Collapse
Affiliation(s)
- Anastasia Bachmann
- BG Trauma Center, Siegfried Weller Institut, Eberhard Karls University Tübingen, Schnarrenbergstr. 95, 72076 Tü̈bingen, Germany.
| | - Matthias Moll
- BG Trauma Center, Siegfried Weller Institut, Eberhard Karls University Tübingen, Schnarrenbergstr. 95, 72076 Tü̈bingen, Germany.
| | - Eric Gottwald
- Institute for Biological Interfaces, Karlsruhe Institute of Technology, POB 3640, 76021 Karlsruhe, Germany.
| | - Cordula Nies
- Institute for Biological Interfaces, Karlsruhe Institute of Technology, POB 3640, 76021 Karlsruhe, Germany.
| | - Roman Zantl
- GmbH, Am Klopferspitz 19, 82152 Martinsried, Germany.
| | - Helga Wagner
- GmbH, Am Klopferspitz 19, 82152 Martinsried, Germany.
| | - Britta Burkhardt
- BG Trauma Center, Siegfried Weller Institut, Eberhard Karls University Tübingen, Schnarrenbergstr. 95, 72076 Tü̈bingen, Germany.
| | - Juan J Martínez Sánchez
- BG Trauma Center, Siegfried Weller Institut, Eberhard Karls University Tübingen, Schnarrenbergstr. 95, 72076 Tü̈bingen, Germany.
| | - Ruth Ladurner
- Clinic for General, Visceral and Transplantation Surgery, Eberhard Karls University Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
| | - Wolfgang Thasler
- Department of Surgery, Ludwig-Maximilians-University of Munich Hospital Grosshadern, 81377 Munich, Germany.
| | - Georg Damm
- Department for General, Visceral and Transplantation Surgery, Charité Medical University Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
| | - Andreas K Nussler
- BG Trauma Center, Siegfried Weller Institut, Eberhard Karls University Tübingen, Schnarrenbergstr. 95, 72076 Tü̈bingen, Germany.
| |
Collapse
|
53
|
Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR. Microengineered liver tissues for drug testing. ACTA ACUST UNITED AC 2015; 20:216-50. [PMID: 25617027 DOI: 10.1177/2211068214566939] [Citation(s) in RCA: 86] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2014] [Indexed: 01/09/2023]
Abstract
Drug-induced liver injury (DILI) is a leading cause of drug attrition. Significant and well-documented differences between animals and humans in liver pathways now necessitate the use of human-relevant in vitro liver models for testing new chemical entities during preclinical drug development. Consequently, several human liver models with various levels of in vivo-like complexity have been developed for assessment of drug metabolism, toxicity, and efficacy on liver diseases. Recent trends leverage engineering tools, such as those adapted from the semiconductor industry, to enable precise control over the microenvironment of liver cells and to allow for miniaturization into formats amenable for higher throughput drug screening. Integration of liver models into organs-on-a-chip devices, permitting crosstalk between tissue types, is actively being pursued to obtain a systems-level understanding of drug effects. Here, we review the major trends, challenges, and opportunities associated with development and implementation of engineered liver models created from primary cells, cell lines, and stem cell-derived hepatocyte-like cells. We also present key applications where such models are currently making an impact and highlight areas for improvement. In the future, engineered liver models will prove useful for selecting drugs that are efficacious, safer, and, in some cases, personalized for specific patient populations.
Collapse
Affiliation(s)
- Salman R Khetani
- Department of Mechanical Engineering, Colorado State University, Fort Collins, CO, USA School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA
| | - Dustin R Berger
- School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA
| | - Kimberly R Ballinger
- Department of Mechanical Engineering, Colorado State University, Fort Collins, CO, USA
| | - Matthew D Davidson
- School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA
| | - Christine Lin
- School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA
| | - Brenton R Ware
- School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA
| |
Collapse
|
54
|
Ogihara T, Iwai H, Inoue Y, Katagi J, Matsumoto N, Motoi-Ohtsuji M, Kakiki M, Kaneda S, Nagao T, Kusumoto K, Ozeki E, Jomura T, Tanaka S, Ueda T, Ohta K, Ohkura T, Arakawa H, Nagai D. Utility of human hepatocyte spheroids for evaluation of hepatotoxicity. ACTA ACUST UNITED AC 2015. [DOI: 10.2131/fts.2.41] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- Takuo Ogihara
- Spheroid Working Group, Safety Evaluation Forum
- Laboratory of Biopharmaceutics, Faculty of Pharmacy, Takasaki University of Health and Welfare
| | - Hisakazu Iwai
- Spheroid Working Group, Safety Evaluation Forum
- Drug Development Center, Sanwa Kagaku Kenkyusho Co., Ltd
| | | | - Jun Katagi
- Spheroid Working Group, Safety Evaluation Forum
- Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd
| | - Norihito Matsumoto
- Spheroid Working Group, Safety Evaluation Forum
- Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd
| | - Makiko Motoi-Ohtsuji
- Spheroid Working Group, Safety Evaluation Forum
- Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd
| | - Motoharu Kakiki
- Spheroid Working Group, Safety Evaluation Forum
- Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd
| | - Shinya Kaneda
- Spheroid Working Group, Safety Evaluation Forum
- Naruto Research Institute, Otsuka Pharmaceutical Factory, Inc
| | - Takuya Nagao
- Spheroid Working Group, Safety Evaluation Forum
- Environmental Evaluation Business Division, Sumika Chemical Analysis Service, Ltd
| | - Kumiko Kusumoto
- Spheroid Working Group, Safety Evaluation Forum
- Department of Pathology, Osaka City University Medical School
| | - Emiko Ozeki
- Spheroid Working Group, Safety Evaluation Forum
- Research and Development, Toyo Gosei Co., Ltd
| | - Tomoko Jomura
- Spheroid Working Group, Safety Evaluation Forum
- Research and Development, Toyo Gosei Co., Ltd
| | - Sho Tanaka
- Spheroid Working Group, Safety Evaluation Forum
- Safety Assessment Unit, Toxicological Laboratory, Public Interest Incorporated Foundation BioSafety Research Center
| | - Tadayoshi Ueda
- Spheroid Working Group, Safety Evaluation Forum
- Research & Development Division, Dainippon Sumitomo Pharma Co., Ltd
| | - Kunihiro Ohta
- Spheroid Working Group, Safety Evaluation Forum
- Pre-Clinical Research Department, Chugai Pharmaceutical Co., Ltd
| | - Takako Ohkura
- Spheroid Working Group, Safety Evaluation Forum
- Clinical Development Division, Maruishi Pharmaceutical, Co., Ltd
| | - Hiroshi Arakawa
- Spheroid Working Group, Safety Evaluation Forum
- Laboratory of Biopharmaceutics, Faculty of Pharmacy, Takasaki University of Health and Welfare
| | - Daichi Nagai
- Spheroid Working Group, Safety Evaluation Forum
- Pharmaceutical Research Laboratories, Nippon Kayaku Co., Ltd
| |
Collapse
|